ArticlePituitary2026
Subsequent primary malignancies in patients with initial diagnosis of pituitary adenoma: a surveillance, epidemiology, and end results (SEER) data analysis.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pituitary T-lymphoblastic lymphoma combined with pituitary adenoma: a rare case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPituitary adenoma is a frequently encountered intracranial mass that is typically characterized by slow growth and benign behavior. There remains limited knowledge regarding the risk of developing a "subsequent primary malignancy" (SPM) in a patient with a pituitary adenoma. This study assessed the risk of developing a SPM after a pituitary adenoma diagnosis.
methodsThe Surveillance, Epidemiology, and End Results (SEER-17) data registry, which consisted of 9,208,295 patients, was utilized to generate a cohort of 60,677 patients diagnosed with pituitary adenoma to identify patients at risk for a SPM. The SEER patient data was collected from the years 2000 to 2020. Statistical analysis was performed through SEER's stat package and Standardized Incidence Ratios (SIRs) for various malignancies after the diagnosis of primary pituitary adenoma were obtained. We also collected basic demographic, surgical, and postoperative data.
resultsOf the 60,677 patients, 4067 (6.7%) received a diagnosis of a SPM, which correlates to a higher risk than the general population (SIR, 1.1, 99% CI, 1.06-1.15). Patients with a pituitary adenoma had an increased risk of the following cancers: lymphatic and hematopoietic (SIR, 1.25; 99% CI, 1.09-1.41), kidney and renal pelvis (SIR, 1.45; 99% CI, 1.2-1.74), cutaneous melanoma (SIR, 1.36; 99% CI, 1.15-1.16), and thyroid cancer (SIR, 2.76; 99% CI, 2.32-3.26). Additionally, females were more predisposed to the following cancers: Digestive system (SIR, 1.19; 99% CI, 1.11-1.25), and non-Hodgkin's Lymphoma (SIR, 1.41; 99% CI, 1.04-1.88).
conclusionUtilizing the SEER database, we have discovered an increased risk of SPM in patients with pituitary adenoma. Supplementary research may be done to determine any shared genetic abnormalities between the development of pituitary adenoma and these SPMs. Additionally, further research of the endocrinological effects of pituitary adenoma and potential associations to SPMs should be studied.
Indexed as
Identifiers
41663675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.